Catherine took over the role as Chair of the Board in December 2020, having previously served as a Non-Exec Director. She has over 25 years of biotech and pharmaceutical industry experience, 12 of which were within the pharma industry leading drug development programmes in hypertension, heart failure, Parkinson’s Disease and HIV. Since 1999, she has worked extensively to commercialise novel technologies in the life sciences.
Catherine joined the scientific founders to establish the biotech company Exonate where she is CEO. Catherine has a degree in medicine from Birmingham University and in 2008 was awarded the OBE for services to technology and innovation.